Drug
Dextromethorphan - quinidine combination clinical trials
Also written AVP-923.
- studies test it
- 5
- open now
- 0
- in phase 3
- 3
- first study started
- 2001
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
5 studies that test it; most in 2001 (1)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2015 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Avanir Pharmaceuticals (4) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses dextromethorphan - quinidine combination is read from its arms, and is right about nine times in ten.
Testing it · 5
- Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult SubejctsCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02402595Written as AVP-923
- Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult ParticipantsCompletedPhase 1Avanir PharmaceuticalsNCT03381664Written as AVP-923
- Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)CompletedPhase 3Avanir PharmaceuticalsNCT00056524Written as AVP-923
- Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis PatientsCompletedPhase 3Avanir PharmaceuticalsNCT00050232Written as AVP-923
- Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALSCompletedPhase 3Avanir PharmaceuticalsNCT00021697Written as AVP-923
Given in every arm · 1 — dextromethorphan - quinidine combination is usual care beside what is tested
As the comparator · 2 — what is tested is compared with dextromethorphan - quinidine combination
- A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy VolunteersCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02174835Written as AVP-923
- A Phase 1 Study Comparing AVP-786 With AVP-923CompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02336347Written as AVP-923
Codes
What other systems call dextromethorphan - quinidine combination · ClinicalTrials.gg INT004864
- MeSH (NLM) C507057dextromethorphan - quinidine combinationOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C507057 | dextromethorphan - quinidine combination | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.